+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating centhaquine citrate LYFAQUIN1, a novel drug being studied as a resuscitative agent for adults with hypovolemic shock, which is a life-threatening condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study aims to assess the safety and efficacy of centhaquine when added to the standard shock treatment. Centhaquine acts on specific receptors to improve blood flow and reduce vascular resistance, with prior studies showing promising effects on blood pressure, lactate levels, cardiac output, and mortality in animal models. Participants aged 18 years or older with hypovolemic shock and low systolic blood pressure 90 mmHg or lower will receive centhaquine intravenously at a dose of 0.01 mgkg body weight over one hour, in addition to standard care such as fluid resuscitation and vasopressors. A second dose may be given if blood pressure remains low, with no more than three doses in 24 hours and treatment continuing up to two days after enrollment. Each patient will receive between one and six doses within the first 48 hours. Throughout hospitalization, participants will be monitored closely until discharge or up to seven days after joining the trial. Researchers will assess safety by tracking adverse events and efficacy by measuring blood pressure, lactate levels, base deficit, ICU stay duration, ventilator use, urine output, mortality, organ dysfunction scores, respiratory distress, and neurological status. Statistical analyses will compare patient outcomes to understand centhaquines effects as an addition to standard hypovolemic shock treatment.

Age: 18Years +All GendersPhase 4
17 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations